Genomic Predictors of Recurrent Pregnancy Loss
GPRPL
Large Scale Genome Sequencing and Integrative Analyses to Define Genomic Predictors of Recurrent Pregnancy Loss
2 other identifiers
observational
500
1 country
10
Brief Summary
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2021
Longer than P75 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2021
CompletedFirst Submitted
Initial submission to the registry
June 29, 2022
CompletedFirst Posted
Study publicly available on registry
July 5, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
February 11, 2026
February 1, 2026
5.3 years
June 29, 2022
February 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Determine genetic etiology for Recurrent Pregnancy Loss
The WGS tool will be used to analyze the POC sample and parental blood samples to determine the clinical reportable genetic cause for RPL
5 years
Eligibility Criteria
Couples who have had two or more previous pregnancy losses and have undiagnosed cause of recurrent pregnancy loss.
You may qualify if:
- Women with loss of a current singleton pregnancy at \< 20 0/7 weeks gestation, documented by ultrasonography or histopathological examination
- History of one or more prior pregnancy losses
- Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase
You may not qualify if:
- History of parental karyotype abnormalities
- History of antiphospholipid antibody syndrome
- Evidence of uncontrolled diabetes
- Evidence of uncontrolled thyroid disease
- History of autoimmune disease related to pregnancy loss (e.g., systemic lupus erythematosus, rheumatoid arthritis)
- History of uterine anomalies
- History of cervical insufficiency
- Cohort B - Maternal Effect Gene Cohort
- \- Women with a history of three or more pregnancy losses of unknown cause, with or without a liveborn child
- \- Known etiology for pregnancy loss
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Texas at Austincollaborator
- Penn State Universitycollaborator
- Northwestern Universitycollaborator
- The University of Texas Health Science Center at San Antoniocollaborator
- Wayne State Universitycollaborator
- Columbia Universitycollaborator
- University of Colorado, Denvercollaborator
- University of Chicagocollaborator
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)collaborator
- University of Utahcollaborator
- Yale Universitylead
- Johns Hopkins Universitycollaborator
Study Sites (10)
University of Colorado
Aurora, Colorado, 80045, United States
Yale University
New Haven, Connecticut, 06511, United States
Northwestern University
Chicago, Illinois, 60611, United States
University of Chicago
Chicago, Illinois, 60611, United States
Gaelle Massoud
Baltimore, Maryland, 21205, United States
Wayne State University
Detroit, Michigan, 48201, United States
Columbia University
New York, New York, 10032, United States
Pennsylvania State University
Hershey, Pennsylvania, 17033, United States
University of Texas at Austin
Austin, Texas, 78712, United States
University of Texas at San Antonio
San Antonio, Texas, 78299, United States
Biospecimen
Products of conception and blood or saliva of one or both biological parents
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 29, 2022
First Posted
July 5, 2022
Study Start
September 1, 2021
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
February 11, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share